Boomerang is developing a technology to advance the treatment of autoimmune diseases by harnessing the body’s own “peripheral wiring” to manage inflammation and immune response.
Boomerang Medical Raises $20 Million Series B to Advance Pivotal Trial of Neuromodulation in Inflammatory Bowel Disease
Boomerang Medical, Inc., a women-led bioelectronic medicine company, today announced a $20 million Series B financing co-led by Arboretum Ventures and Hatteras Venture Partners. Proceeds will advance BOOM-IBD2, the first…
Boomerang Medical Awarded “Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” by the Crohn’s & Colitis Foundation
Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” from the Crohn's & Colitis Foundation.
This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.
